18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis

[1]  B. Sharrack,et al.  PET scan in clinically suspected paraneoplastic neurological syndromes: a 6‐year prospective study in a regional neuroscience unit , 2009, Acta neurologica Scandinavica.

[2]  S. Goldsmith.  Update on nuclear medicine imaging of neuroendocrine tumors. , 2009, Future oncology.

[3]  K. Miles.  PET-CT in oncology: making the most of CT , 2008, Cancer imaging : the official publication of the International Cancer Imaging Society.

[4]  A. Alavi,et al.  Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. , 2008, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  V. Lowe,et al.  Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. , 2008, Mayo Clinic proceedings.

[6]  David W Townsend,et al.  Dual-Modality Imaging: Combining Anatomy and Function* , 2008, Journal of Nuclear Medicine.

[7]  Abass Alavi,et al.  Feasibility of Automated Partial-Volume Correction of SUVs in Current PET/CT Scanners: Can Manufacturers Provide Integrated, Ready-to-Use Software? , 2008, Journal of Nuclear Medicine.

[8]  Barry A Siegel,et al.  Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. V. von Schulthess,et al.  Imaging and PET-PET/CT imaging. , 2008, Journal de radiologie.

[10]  H. Nabi,et al.  18F-FDG imaging: pitfalls and artifacts. , 2005, Journal of nuclear medicine technology.

[11]  D. Timmann,et al.  Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration , 2005, Journal of Neurology.

[12]  L. Cinotti,et al.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. , 2004, Brain : a journal of neurology.

[13]  J. Honnorat,et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  R. Voltz,et al.  Diagnosis and Treatment of Paraneoplastic Neurological Disorders , 2004, Oncology Research and Treatment.

[15]  G. Cook,et al.  Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. , 2004, Seminars in nuclear medicine.

[16]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[17]  R. Darnell,et al.  Paraneoplastic syndromes involving the nervous system. , 2003, The New England journal of medicine.

[18]  A. Kuten,et al.  Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  F. Grünwald,et al.  Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[20]  R. Voltz.  Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy , 2002, The Lancet Neurology.

[21]  R. Hughes,et al.  The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. , 2001, Brain : a journal of neurology.

[22]  G. Escaramís,et al.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. , 2001, Brain : a journal of neurology.

[23]  P. Ell,et al.  Clinical role of positron emission tomography in oncology. , 2001, The Lancet. Oncology.

[24]  A. Vighetto,et al.  [18F]Fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti‐Hu antibodies , 2000, Annals of neurology.

[25]  J. Honnorat,et al.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone , 2000, Journal of neurology, neurosurgery, and psychiatry.

[26]  P. Grenier,et al.  Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings. , 1998, AJR. American journal of roentgenology.

[27]  C. Lucchinetti,et al.  Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies , 1998, Neurology.

[28]  W. Mason,et al.  Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. , 1997, Brain : a journal of neurology.

[29]  R. Darnell,et al.  Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies , 1993, The Lancet.

[30]  M. Rosenblum,et al.  Anti‐Hu-Associated Paraneoplastic Encephalomyelitis/Sensory Neuronopathy A Clinical Study of 71 Patients , 1992, Medicine.

[31]  Thomas Beyer,et al.  To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.